TetraKit

Next Generation Theranostics

circles design
molecules

TetraKit: Next Generation Theranostics

Targeted radionuclide therapy is an emerging field that has shown great promise in the treatment of late-stage metastatic cancer. Theranostics combines radionuclide therapy with diagnosis by nuclear imaging. In theranostics, cancer-targeting molecules, known as radiopharmaceuticals, carry radioactive atoms specifically to tumors. Depending on which type of radiation is chosen, physicians can either diagnose the severity and spread of the cancer or treat it by selectively destroying the cancerous tissue. TetraKit is a new, click chemistry based radiochemical platform, which allows for labeling of virtually any cancer-targeting molecule with any radionuclide pair for theranostics. TetraKit Technologies focuses its development program on fluorine-18 and astatine-211 as this pair is the best suited radionuclide pair for PET imaging and targeted alpha-radionuclide therapy. Alpha-therapy has attracted wide interest in current oncology as it succeeded where conventional therapies failed. TetraKit will develop the next generation of theranostic radiopharmaceuticals, which will improve patient care and disease outcomes.

Logo transparent

Latest news

from TetraKit Technologies

November 29, 2022

Radiograf Rådet

This year’s Nobel Prize in chemistry prompted the Danish Newspaper Radiograf Rådet to publish a story about the academic research of Dr. Matthias Herth, our very own CSO, using click chemistry. Check it out (in Danish only) 😊 https://lnkd.in/eddXebf2

#clickchemistry #positronemissiontomography #radiotherapy

Read more

November 22, 2022

Supply At-211

We are pleased to announce an agreement with Rigshospitalet (The National Hospital of Denmark), Department of Clinical Physiology, Nuclear Medicine & PET to supply us with astatine-211 (At-211) for our development programs.

#hospital #medicine #TAT #alphatherapy #alphaisotopes

Read more

October 10, 2022

TRIMT and TETRAKIT

#TRIMT and #TETRAKIT are joining forces to develop 18F-Flutrahexin based on #Nobel Prize awarded #technology. Read more in the press release.

About TRIMT   TRIMT GmbH is a clinical-stage company developing novel radiopharmaceuticals to diagnose and treat life-threatening diseases. The company was founded in early 2021 in Radeberg near Dresden (Germany). TRIMT holds a worldwide exclusive license for various new radioligands based on technologies from the Technical University of Munich.

Read more

Message from the CEO

Andreas Jensen, PhD

Andreas Jensen, PhD

Chief Executive Officer

Message from the CEO

“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”

Message from the CSO

Matthias Herth, PhD

Matthias Herth, PhD

Chief Scientific Officer

Message from the CSO

“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”